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Background: Although statins (STs) are drugs of first choice in hypercholesterolemic patients, especially in those at
high cardiovascular risk, some of them are intolerant to STs or refuse treatment with these drugs. In view of this, we
have evaluated the lipid-lowering effect of a nutraceutical pill containing berberine (BBR) and of ezetimibe, as
alternative treatments, in monotherapy or in combination, in 228 subjects with primary hypercholesterolemia (HCH),
with history of STs intolerance or refusing STs treatment. In addition, since PCSK9 was found up-regulated by STs
dampening their effect through an LDL receptors (LDLRs) degradation, and BBR suppressed PCSK9 expression in
cellular studies, we supplemented the stable lipid-lowering therapy of 30 genotype-confirmed Familial
Hypercholesterolemia heterozygotes (HeFH) with BBR, searching for a further plasma cholesterol reduction. Plasma
lipid pattern was evaluated at baseline and during treatments.
Results: In HCH subjects the nutraceutical pill resulted more effective than EZE in lowering LDL cholesterol
(−31.7% vs −25.4%, P < 0.001) and better tolerated. On treatment, LDL-C level below 3.36 mmol/L (≤130 mg/dl) was
observed in 28.9% of subjects treated with the nutraceutical pill and 11.8% of those treated with EZE (P <0.007). In
the group treated with EZE the subjects carrying the G allele of the g.1679 C > G silent polymorphism of NPC1L1
gene showed a higher response to EZE than homozygous for the common allele (GG + CG: LDL-C −29.4±5.0%, CC
−23.6±6.5%, P <0.001). Combined treatment with these drugs was as effective as STs in moderate doses (LDL
cholesterol −37%, triglycerides −23%). In HeFH patients the addition of BBR resulted in LDL cholesterol reductions
inversely related to those induced by the stable therapy (r =−0.617, P <0.0001), with mean 10.5% further decrease.
Conclusions: The alternative treatments tested in our HCH subjects were rather effective and safe. The findings in
HeFH patients suggest that BBR might act in vivo increasing expression and stability of LDLRs and/or suppressing
PCSK9 expression.
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An elevated level of LDL cholesterol (LDL-C) in plasma is
the major risk factor for cardiovascular disease (CVD) [1].
The HMG-CoA reductase inhibitors (Statins, STs) are the
drugs of first choice to lower plasma cholesterol, especially
in patients at high or very high risk for cardiovascular dis-
ease (CVD), in view of their documented and dose-related
efficacy in reducing CVD morbidity and mortality in both
primary and secondary prevention [2-5]. However, 10-15%
of patients result to be intolerant to any ST, even at low
daily doses, for muscle side effects, ranging from mild myal-
gia without increase of creatine kinase (CK) to more severe
muscle symptoms with significant CK elevations [6,7], and
1-3% show an asymptomatic elevation of transaminases
(AST, ALT) in the absence of clear hepatic toxicity [6].
Some other patients, in primary prevention, refuse STs
treatment since they are worried about possible side effects.
Alternative hypocholesterolemic treatments to be consid-
ered for the above mentioned cases include plant sterols
and stanols, the cholesterol absorption inhibitor ezetimibe,
bile acid sequestrants (especially the well tolerated coleseve-
lam) and some nutraceutical products containing various
associations of red yeast rice, policosanols, phytosterols and
berberine [2,6-8].
When monotherapy results in unsatisfactory lipid-
lowering effect, combined treatment with some of these
products can be prescribed [9].
The aims of this paper were: i) to evaluate the plasma
lipid-lowering effect of a nutraceutical product containing
berberine, policosanols and red yeast rice (BBR/P/RR), in
comparison to that induced by ezetimibe (EZE) as mono-
therapy in subjects with primary polygenic hypercholester-
olemia (HCH) intolerant to STs or refusing treatment with
these drugs; ii) to test the effect of the combined therapy
with BBR/P/RR and EZE on plasma lipid concentrations in
a subgroup of these subjects, low responders to monother-
apy and iii) to search for an additional plasma cholesterol
reduction induced by the supplementation with BBR/P/RR
in a small number of genotype-confirmed patients with het-
erozygous Familial Hypercholesterolemia (HeFH), who
were on stable-dose treatment with STs or STs plus EZE, in
view of the effect of Proprotein Convertase Subtilisin/Kexin
type 9 (PCSK9) on low-density lipoprotein receptor (LDLR)
degradation, the increase of plasma PCSK9 level induced
by STs [10] and the inhibitory effect of BBR on PCSK9 ex-
pression found in human-derived cultured cells [11].
Methods
Subjects
Comparison between the lipid-lowering effect of a
nutraceutical-combined pill containing berberine (BBR/P/RR)
and of ezetimibe (EZE) in monotherapy
Among outpatients attending our Lipid Clinic we con-
sidered eligible for this study subjects with primarypolygenic HCH, diagnosed on the basis of personal and
family studies, who had a negative history of cardiovas-
cular disease and were previously found to be intolerant
to STs or were refusing treatment with these drugs. Car-
diovascular evaluation was performed in each subject by
ECG stress testing and ultrasound examination of the
carotid arteries. The patients with secondary forms of
hyperlipidaemia, including type 2 diabetics, subjects with
monogenic forms of HCH and those with silent ischemia
at ECG stress test and/or arterial carotid atherosclerosis
with more than 40% stenosis or soft plaque morphology
were excluded from the study.
After a three-month run-in period with a plasma lipids
stabilizing diet (poor in saturated fats and cholesterol),
270 subjects were randomized by lot on 2:1 basis either
to a treatment with a nutraceutical-combined pill (con-
taining berberine 500 mg, policosanol 10 mg and red
yeast rice 200 mg; BBR/P/RR) or ezetimibe 10 mg/day
(EZE) for six months.
Plasma lipid concentrations were assessed after diet
(baseline condition) and every two months during treat-
ment, and the mean value of the three determinations of
each lipid parameter was considered for the statistical
comparison. Laboratory analysis was performed “double-
blind” because laboratory operators did not know the
assigned treatment.
Seventy-six subjects on EZE (31 males and 45 females)
completed the six-month follow-up period; eight sub-
jects were excluded for poor compliance and six left the
study for gastrointestinal or biochemical side-effects
(AST/ALT and/or CK elevation). For comparison pur-
poses, each of the 76 subjects on EZE was matched for
gender, age and baseline cholesterol level with two sub-
jects on BBR/P/RR treatment (Table 1). No significant
side-effects were recorded in the group of subjects re-
ceiving the nutraceutical pill.Combined lipid-lowering effect of BBR/P/RR and EZE
As an extension of the former study, 26 subjects (57.7 ±
9.0 years of age, BMI 23.3 ± 3.3 kg/m2), 12 (5 males and
7 females) on BBR/P/RR and 14 (7 males and 7 females)
on EZE as monotherapy, received combined treatment
with the two products for a further three-month period.
These subjects were selected from those who, during
monotherapy, had a percent decrease of LDL-C below
the median level (−29%) of the distribution of the values
obtained in the whole group of subjects on mono-
therapy (n. 152 on BBR/P/RR and n.76 on EZE), and
gave their consent to combined treatment. Plasma lipid
concentrations were determined monthly and for each
lipid parameter the mean value of the three measures
was compared with the mean value obtained during
mono-therapy.
Table 1 Clinical features and baseline plasma lipid
concentrations of the two groups of subjects with
primary hypercholesterolemia (HCH) treated with BBR/P/
RR or EZE for six months
BBR/P/RR EZE P
Males/Females 62/90 31/45
Age (years) 57.3 ± 12.1 58.3 ± 12.3 NS
BMI (kg/m2) 23.9 ± 2.9 23.5 ± 2.8 NS
Arterial hypertension 30.2% 31.5% NS
Carotid atherosclerosis* 26.3, 48.0, 3.9% 31.5, 51.3, 3.9% NS
TC (mmol/L) 7.63 ± 0.50 7.72 ± 0.49 NS
LDL-C (mmo/L) 5.36 ± 0.48 5.36 ± 0.52 NS
HDL-C (mmo/L) 1.55 ± 0.35 1.57 ± 0.34 NS
non-HDL-C (mmol/L) 6.07 ± 0.54 6.15 ± 0.55 NS
TG (mmol/L)† 1.46 (1.22-1.90) 1.67 (1.24-2.12) NS
*Percent of subjects with increased intima-media thickness, with fibrous-
calcific plaques with less than 30% stenosis and with fibrous-calcific plaques
with 30-40% stenosis, respectively. †Median (interquartile range). NS: not
significant.
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BBR/P/RR supplementation in patients with heterozygous
Familial Hypercholesterolemia (HeFH) on stable-dose
treatment with statins (STs) or statins plus ezetimibe
(STs + EZE)
Thirty patients with HeFH previously genetically charac-
terized in our laboratory (21 males and 9 females, 56.5 ±
9.2 years of age, 12 with receptor-defective (RD) and 18
with receptor-negative (RN) LDLR gene mutations [12]),
who were on stable-dose treatment with the maximal
tolerated dose of STs or STs plus EZE for one year or
more [see Additional file 1: Table S1], received BBR/P/
RR pill for three months as supplementary therapy.
Plasma lipid concentrations were determined monthly
and for each lipid parameter the mean value of the three
measures was compared with the mean value obtained
during STs or STs plus EZE therapy.
Written informed consent was obtained from each
participant and the study protocol was approved by the
local institutional human investigation committee.Biochemical analysis
Plasma concentrations of total cholesterol (TC) and trigly-
cerides (TG) were measured by standardized enzymatic
methods. High-density lipoprotein cholesterol (HDL-C)
was measured in plasma supernatant after precipitation of
apoB-containing lipoproteins by phosphotungstate-MgCl2.
Low-density lipoprotein cholesterol (LDL-C) was calcu-
lated by the Friedewald's formula. Serum non-HDL-C
concentrations were calculated by subtracting HDL-C
concentrations from TC concentrations.Genotyping for the g.1679 C > G polymorphism of
NPC1L1 gene
Genomic DNA was extracted from peripheral blood leu-
kocytes using standard method. The screening for the si-
lent polymorphism g.1679 C > G (c.816 C > G, L272L)
of NPC1L1 gene [GenBank: NG_013088.1] was per-
formed by amplification of the central portion of exon 2
using the following primers: 5’-CCA GCT AGG GTC
TGG ACA ACT CC -3’ (forward) and 5’-GGA TGA
CAG ATA GCA CCA AGA TGG -3’ (reverse). Since the
presence of G allele eliminates a Taq I restriction site
(T/CGA), the PCR product was incubated with 10 U of
Taq I (New England Biolabs, Beverly, MA, USA) at 65°C
for 1 h and the digestion products (387 and 269 bp for
the C allele and 656 bp for the G allele) were separated
on 2% agarose gel.
Statistical analyses
The statistical analyses were performed using PASW
18.0 statistical software package (SPSS Inc., Chicago, IL).
Data are presented as mean ± SD for continuous vari-
ables, medians and interquartile ranges for triglycerides
which have a skewed distribution. Differences in the dis-
tribution of categorical variables were assessed by χ2
with Yates’s correction or Fisher's exact tests. Triglycer-
ide values, which were not normally distributed, were
logarithmically transformed before analysis. The statis-
tical significance of the differences between baseline and
treatment lipid values, as well as between monotherapy
(BBR/P/RR or EZE) and combined treatment (BBR/P/RR
plus EZE), was assessed by Student's t-test for paired
data or Wilcoxon test. The significance of the differences
between treatments (BBR/P/RR vs EZE) was evaluated
comparing percent variations of the lipid parameters by
Student’s t-test or Mann–Whitney test, as appropriate.
In patients with HeFH, on stable-dose treatment with
STs or STs plus EZE, the effect of additional therapy
with BBR/P/RR was assessed by ANOVA and multiple
comparisons among pairs of means were performed by
t-tests with Bonferroni's correction. Percent variations
induced by STs or STs plus EZE were compared with
those induced by BBR/P/RR supplementation by Stu-
dent’s t-test for paired data or Wilcoxon test. The correl-
ation between changes induced by STs or STs plus EZE
and those induced by BBR/P/RR supplementation was
evaluated by Pearson’s and Spearman’s tests.
Results
Comparison between the lipid-lowering effect of a
nutraceutical-combined pill containing berberine (BBR/P/RR)
and of ezetimibe (EZE) in monotherapy
Table 2 shows the effects on lipid parameters respect-
ively induced by the treatment with BBR/P/RR and EZE
in the two groups of subjects with primary HCH. The
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lipid variations showed that BBR/P/RR was more effect-
ive than EZE in reducing TC, LDL-C and non-HDL-C
levels, and showed a tendency to lower TG more than
EZE. The percentage of subjects with more than 30% de-
crease of LDL-C and non-HDL-C resulted to be higher
in the group treated with BBR/P/RR than in the group
treated with EZE (P <0.0001) (Figure 1). No significant
effect on HDL-C level was recorded with either treat-
ment, although a tendency to increase was observed in
patients treated with EZE. On treatment, LDL-C level
below 3.36 mmol/L (≤130 mg/dl) was observed in 28.9%
of subjects treated with BBR/P/RR and 11.8% of those
treated with EZE (P <0.007); non-HDL-C level below
4.14 mmol/L (≤160 mg/dl) was observed in 44.0% of
subjects treated with BBR/P/RR and in 21.0% of those
treated with EZE (P <0.002). A DNA sample was avail-
able for 70 out of 76 subjects treated with EZE. These
subjects were genotyped for the g.1679 C > G silent
polymorphism of the NPC1L1 gene, which had previ-
ously been found to influence the cholesterol-lowering
effect of EZE [13,14]. Indeed, the carriers of the G allele
(3 GG and 23 CG) showed a higher response to EZE
than homozygous for the common allele (44 CC) (LDL-
C −29.4±5.0% vs −23.6±6.5%, P <0.001).Combined lipid-lowering effect of BBR/P/RR and EZE
Table 3 shows the lipid-lowering effect of the combined
therapy with BBR/P/RR and EZE in 26 subjects low-
responders to monotherapy. In comparison to monother-
apy, the combined treatment caused a further mean de-
crease of TC, LDL-C, non-HDL-C and TG of −9.7%,
-13.6%, –12.5% (P <0.001) and −4.5% (P <0.005), respect-
ively. During combined treatment 50% of the subjects
reached an LDL-C level below 3.36 mmol/L (≤130 mg/dl)
and 65.4% a non-HDL-C below 4.14 mmol/L (≤160 mg/dl).
This combination was well tolerated and did not induce
side effects.Table 2 Comparison between treatments with BBR/P/RR and
months follow-up
BBR/P/RR
Plasma lipids (mmo/L) Baseline On treatment Percent cha
TC 7.63 ± 0.50 5.77 ± 0.49* −24.2 ± 5
LDL-C 5.36 ± 0.48 3.66 ± 0.48* −31.7 ± 7
HDL-C 1.55 ± 0.35 1.54 ± 0.37 −0.64 ± 7
non-HDL-C 6.07 ± 0.54 4.22 ± 0.53* −30.3 ± 6
TG 1.46 (1.22-1.90) 1.12 (0.95-1.41)* −19.5 ± 1
Data are means ± SD or medians (interquartile ranges). *P < 0.001 vs baseline values
differences between percent changes induced by BBR/P/RR and by EZE treatmentsSupplementary therapy with BBR/P/RR in HeFH patients
on stable-dose treatment with STs or STs + EZE
Table 4 shows plasma lipid concentrations at baseline,
during treatment with a stable dose of STs or STs plus
EZE and after BBR/P/RR supplementation in 30 HeFH
patients attending our Lipid Clinic. Tendon xanthoma-
tosis, coronary artery disease and previous coronary
revascularization were present in 17%, 33% and 25% of
HeFH-RD patients and in 89%, 61% and 33% of HeFH-
RN patients, respectively.
On average BBR/P/RR significantly further decreased
TC, LDL-C, non-HDL-C and TG levels by 8.1%, 10.5%,
9.7% and 5.4%, respectively. These effects were not sig-
nificantly different between HeFH-RD and HeFH-RN
patients. The additional percent decrease of plasma
LDL-C induced by BBR/P/RR (calculated as the differ-
ence between percent decrease induced by treatment
with STs or STs + EZE supplemented with BBR/P/RR
minus that induced by STs or STs + EZE) showed a wide
inter-individual variability (from −22.5% to −2.0%). Fif-
teen patients, showing more than 10% decrease of LDL-
C level with respect to percent decrease observed during
STs or STs + EZE therapy, were considered good-
responders to BBR/P/RR treatment, while two patients,
showing less than 5% decrease, were considered non-
responders. During therapy with STs or STs + EZE an
LDL-C value below 3.36 mmol/L (≤130 mg/dl) and non-
HDL-C below 4.14 mmol/L (≤160 mg/dl) was reached
only in 3 and 6 patients, respectively; after the addition
of BBR/P/RR the patients reaching these levels were 11
and 14, respectively. In order to define whether the mag-
nitude of the response to BBR/P/RR was affected by the
pre-existing treatment with STs or STs + EZE, we plot-
ted the percentage response to STs or STs + EZE against
the additional LDL-C reduction (given as percentage)
induced by BBR/P/RR. We observed a highly significant
inverse correlation between these parameters with both
Pearson’s and Spearman’s tests (r =−0.617 and
r =−0.611, respectively; P <0.0001) (Figure 2).EZE on plasma lipid concentrations in HCH patients. Six
EZE †P
nge Baseline On treatment Percent change
.2 7.72 ± 0.49 6.25 ± 0.51* −19.0 ± 4.6 < 0.001
.0 5.36 ± 0.52 4.00 ± 0.52* −25.4 ± 6.4 < 0.001
.2 1.57 ± 0.34 1.58 ± 0.35 +1.24 ± 6.9 NS
.5 6.15 ± 0.55 4.66 ± 0.58* −24.2 ± 5.9 < 0.001
6.1 1.67 (1.24-2.12) 1.43 (1.08-1.80)* −14.9 ± 11.5 NS
(Student’s t test for paired data or Wilcoxon test); †P: significance of the












Figure 1 Percent distribution of subjects treated with BBR/P/RR
or EZE according to the percent decreases of LDL-C and
non-HDL-C.
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Twenty-two percent of the subjects selected for treat-
ment with BBR/P/RR or EZE had a previous history of
intolerance to any STs, even at low dosage, while the
others refused STs treatment for fear of possible side
effects. Since at present there are no clinical data on the
reduction of CVD events with these treatments, we en-
rolled for this study only subjects with primary HCH
and moderate CVD risk. The BBR/P/RR combination
resulted more effective than EZE, in terms of reduction
of TC, LDL-C and non-HDL-C (Figure 1); neither of the
treatments significantly affected HDL-C concentrations,
although a small increase was observed with EZE, but
both reduced TG levels to the same extent (Table 2).
Moreover, BBR/P/RR pill resulted to be better tolerated
than EZE monotherapy. Previous studies, placebo or
dietary regimen controlled, which evaluated the plasma
lipid-lowering effects of this nutraceutical pill in groups
of various sizes of middle-aged or elderly subjects, with
moderate forms of mixed hyperlipidemia, had given vari-
able results (decrease of LDL-C from −10.8% to −31%
and TG from −9.5% to 26%) [15-18]. In our group of
subjects with a more severe form of primary HCH trea-
ted with BBR/P/RR for six months, LDL-C, non-HDL-C
and TG were reduced by 32%, 30% and 19.5%, respect-
ively. Discrepancy with some of the previous findingsTable 3 Comparison between plasma lipid changes induced b
(n. 12 subjects) and combined therapy with BBR/P/RR plus EZ
Lipid parameter Baseline Monotherapy %
TC (mmol/L) 7.74 ± 0.40 6.34 ± 0.40* −1
LDL-C (mmol/L) 5.47 ± 0.51 4.19 ± 0.48* −2
HDL-C (mmol/L) 1.58 ± 0.40 1.59 ± 0.42 +0
non-HDL-C (mmol/L) 6.15 ± 0.59 4.75 ± 0.57* −2
TG (mmol/L) 1.48 (1.08-1.89) 1.12 (0.95-1.47)* −1
Values are means ± SD or medians (interquartile ranges). *P <0.001 vs baseline valu
percent changes induced by monotherapy and by combined therapy (Student’s t temay be due to several factors, including the type of
hyperlipidemia (isolated more severe HCH versus
mixed hyperlipidemia), difference in body weight and
glucose tolerance, compliance to medication and con-
comitant therapy with drugs interfering with lipopro-
tein metabolism.
In relation to the composition of the nutraceutical pill,
the mechanisms underlying its lipid-lowering effect must
be considered for each single component.
Chinese red yeast rice extract is a medicinal agent
made by fermenting the yeast, Monascus purpureus,
over rice. Monascus yeast produces a family of sub-
stances called monacolins, including monacolin K (also
called mevilonin or lovastatin), capable of inhibiting the
enzyme HMG-CoA reductase, and it also contains
monounsaturated fatty acids, isoflavones and phytoster-
ols, all capable of lowering LDL-C. Several studies, in-
cluding one meta-analysis, all support the beneficial
effect of red yeast rice on blood lipid profile in hyperlip-
idemic subjects [19] and this effect was confirmed in
patients intolerant to STs, where red yeast rice prepara-
tions induced a dose-dependent decrease of LDL-C,
from 21% to 30%, without serious adverse effects in
most of the cases [20,21]. However, in all these studies
red yeast rice preparations, containing a variable amount
of monacolin K and other monacolins per fixed dose of
red yeast rice [22], were used in daily doses, ranging
from 0.6 to 4.8 g, much higher than that present in the
nutraceutical pill administered in this study (200 mg
with standardized content of 3 mg monacolin K),
accounting for some reports of myopathy in patients
treated with high doses of red yeast rice.
Policosanol is a mixture of long-chain primary alco-
hols isolated from sugar cane wax. Apart from early clin-
ical studies conducted by Cuban groups showing
beneficial effects of the policosanol on the plasma lipid
profile [19], more recent randomized controlled trials in
hyperlipidemic Caucasian subjects did not find any
lipid-lowering effect of this compound either in mono-
therapy in doses ranging from 10 to 80 mg/day [23] or
in combination with STs [24]. On the basis of these find-
ings, we believe that the 10 mg of policosanol in oury monotherapy with BBR/P/RR (n. 14 subjects) or EZE
E in HCH patients
changes Combined therapy % changes {P
8.0 ± 3.5 5.59 ± 0.40† −27.7 ± 3.8 < 0.001
3.5 ± 3.5 3.44 ± 0.44† −37.1 ± 4.5 < 0.001
.17 ± 8.2 1.60 ± 0.42 +1.10 ± 5.7 NS
2.8 ± 3.8 3.98 ± 0.49† −35.3 ± 4.2 < 0.001
8.6 ± 15.5 1.09 (0.94-1.35)† −23.1 ± 12.9 < 0.005
es and †P <0.001 vs monotherapy; {P: significance of the differences between
st for paired data or Wilcoxon test, respectively). NS: not significant.
Table 4 Plasma lipid changes induced by supplementary treatment with BBR/P/RR in 30 HeFH patients on stable-dose
therapy with STs or STs plus EZE




plus BBR/P/RR % changes after
BBR/P/RR addition
P
TC (mmol/L) 9.94 ± 1.49 6.35 ± 0.99† −35.5 ± 8.5 5.54 ± 0.77†{ −43.7 ± 7.3 < 0.001
LDL-C (mmol/L) 7.91 ± 1.35 4.47 ± 0.94† −42.6 ± 10.9 3.65 ± 0.71†} −53.2 ± 8.7 < 0.001
HDL-C (mmol/L) 1.29 ± 0.39 1.30 ± 0.35 +2.6 ± 10.3 1.33 ± 0.38 +4.3 ± 11.4 NS
non-HDL-C (mmol/L) 8.65 ± 1.47 5.05 ± 1.06† −41.2 ± 9.8 4.20 ± 0.84†{ −50.9 ± 8.7 < 0.001
TG (mmol/L) 1.48 (0.98-2.30) 1.27 (0.89-2.03) −17.7 ± 17.2 1.11 (0.83-1.63)* −23.1 ± 21.2 < 0.03
Values are means ± SD or medians (interquartile ranges). *P <0.05 vs baseline, †P< 0.02 vs baseline; {P< 0.05 vs STs and STs + EZE, }P< 0.02 vs STs and STs + EZE
(ANOVA and multiple comparisons among pairs of means by t-tests with Bonferroni's correction). }P: significance of the differences between percent changes
induced by STs or STs + EZE and those induced by treatment supplementation with BBR/P/RR (Student’s t test for paired data or Wilcoxon test).
NS: not significant.
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effect.
The lipid-lowering effect of BBR, an isoquinoline alkaloid
extracted from many herbal plants (Rhizoma coptidis,
Hydrastis Canadensis, Berberis vulgaris), was reported for
the first time in Chinese patients with type IIa or IIb hyper-
lipidemia treated with BBR alone (500 mg twice per day).
In that study BBR decreased TC, LDL-C and TG by 20%,
25% and 8% in type IIa and by 29.5%, 11% and 48% in type
IIb, respectively [25]. Studies in animals and cultured cells
had clarified the mechanisms underlying the effects of this
drug. BBR increases hepatic LDLR mRNA and LDLR pro-
tein stabilizing mRNA by post-transcriptional mechanism,
which involves the activation of the extracellular signal-
regulated kinase (ERK) signaling pathway [25]. The activa-
tion of ERK inhibits the expression of hnRNP I (het-
erogeneous nuclear ribonucleo-protein I) and KSRP
(KH-type splicing regulatory protein), which, inter-
acting with cis-regulatory sequences (AU-rich ele-
ments) in the proximal section of the 3’ untranslated-10 -20 -30 -40 -50 -60 
-5 



























Figure 2 Pearson’s correlation between percent decrease of
LDL-C induced by STs or STs/EZE and the additional percent
decrease due to BBR/P/RR supplementation in genotype-
confirmed HeFH patients.region (UTR) of LDLR mRNA, reduce its stability [26].
By the activation of the JNK/c-jun pathway, BBR also
increases the transcriptional activity of LDLR promoter
[27]. In addition, BBR may reduce plasma lipids inhi-
biting hepatic cholesterol and triglyceride synthesis
through the activation of AMP-activated protein kinase
(AMPK), which inactivates HMG-CoA reductase and
Acetyl-CoA carboxylase enzymes [28].
In the original study of hypercholesterolemic type IIa
patients, the 25% decrease of LDL-C levels was obtained
with a dose of BBR two-fold that present in our nutraceut-
ical pill [25]. Moreover, Cicero et al. [15] in their hyperlipid-
emic patients, using 500 mg/day of BBR alone, observed
only a 20% decrease in LDL-C. In view of these findings
and of the results obtained in the present study with low
dose of both red yeast rice and BBR, we can suppose a syn-
ergistic effect of these two components on hepatic lipids
synthesis inhibition, in addition to the BBR-mediated in-
crease of LDLR mRNA and LDLR protein abundance.
EZE inhibits the absorption of dietary and biliary chol-
esterol, as well as of plant sterols, at the brush border of
jejunal enterocytes, and the re-absorption of the biliary
cholesterol by the liver cells, selectively blocking the ac-
tivity of NPC1L1 transporter in enterocytes and canali-
cular membranes of hepatocytes [29]. By reducing the
amount of chylomicron cholesterol supplied to the liver,
EZE decreases hepatic cholesterol content, leading to
increased LDLRs expression, which results in an
increased uptake of LDL from the plasma and decreased
circulating LDL-C levels [30]. However, the effect of
EZE on LDLRs expression is partially counteracted by
an increase in cholesterol synthesis, which is suppressed
by STs [31]. This explains the additive effect on LDL-C
lowering of EZE and STs when these drugs were co-
administered [32].
From a meta-analysis of eight randomized controlled
trials [33] and from 14 more recent studies, which as a
whole investigated 4110 hyperlipidemic subjects (LDL-C
4.32±0.49 and TG 1.90±0.75 mmol/L) treated for
12 weeks, it results that monotherapy with 10 mg/day of
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spectively, and increase HDL-C by 3%. In subjects we
treated with EZE, although in a context of a large inter-
individual variability (decrease in LDL-C from −9.2% to
−38.8%), we unexpectedly observed a higher mean per-
cent reduction of plasma LDL-C (−25.4%). Possible
explanations for these results, in comparison with those
reported above, were the higher baseline levels of LDL-C
[34] of our patients, a more prolonged treatment and
the genetic background of our population, with refer-
ence to some single nucleotide polymorphisms or non-
synonymous sequence variants of NPC1L1 gene asso-
ciated with a higher LDL-C lowering response to EZE
[14]. However, this last assumption must be considered
with caution, since in the present paper we have investi-
gated only one genetic variant and have found a fre-
quency of the minor allele similar to that detected in
other populations [13].
In the small subgroup of our subjects, who were con-
sidered relatively low responders to monotherapy, the
combined treatment with BBR/P/RR and EZE decreased
LDL-C by 37%, non-HDL-C by 35% and TG by 23%
(Table 3), owing to the inhibition of cholesterol absorp-
tion associated with a suppression of hepatic lipid syn-
thesis, causing a more sustained expression of LDLRs.
The effects of the combined treatment were similar to
those induced by simvastatin 20 mg/day, atorvastatin
10 mg/day and rosuvastatin 5 mg/day and higher than
those obtained with pravastatin 40 mg/day in patients
with primary HCH [35], suggesting a satisfactory alter-
native treatment of patients intolerant to STs.
In our group of genotype-confirmed HeFH patients,
who were on stable treatment with STs or STs/EZE
combination (see Additional file 1: Table S1), the supple-
mentation of the treatment with the nutraceutical pill
containing BBR, although in the context of a large inter-
individual variability, induced a mean 10.5% further de-
crease of plasma LDL-C level [Table 4]. The mechanisms
underlying this effect are likely to be BBR-mediated and
might consist in: i) an increased expression of LDLRs
[27] encoded by the wild type allele, coupled with their
prolonged half-life [25,26] and/or ii) a reduced expres-
sion of PCSK9 [11] and consequently a lower LDLRs
degradation (see below).
PCSK9 is a serine protease expressed in the liver and
intestine, which after auto-cleavage in endoplasmic
reticulum (ER) moves to the cell surface and is secreted
into the plasma [10,36]. Circulating PCSK9 binds to
LDLR on the cell surface of hepatocytes, the LDLR/
PCSK9 complex is internalized into the cell and in lyso-
somes LDLR undergo a PCSK9-mediated degradation.
PCSK9, independently from endocytosis, can also bind
LDLRs within the cell targeting them for degradation in
lysosomes [36]. The role of PCSK9 as post-transcriptionalregulator of the amount of LDLRs in the liver is sup-
ported by the finding that gain of function mutations of
PCSK9 in humans cause hypercholesterolemia, while loss
of function mutations cause hypocholesterolemia, and re-
spectively increase and reduce cardiovascular risk [10,36].
The promoter region of PCSK9 gene contains the
HNF1 and SRE sites, which respectively bind the trans-
activation proteins Hepatocyte Nuclear Factor 1α
(HNF1α) and Sterol Regulatory Element Binding Pro-
tein 2 (SREBP2). HNF1α is essential for PCSK9 basal
transcription and for SREBP2-induced maximal gene
expression in response to intracellular cholesterol de-
pletion [37].
Treatment with STs, by inhibiting cholesterol synthe-
sis, causes cholesterol depletion in the liver and conse-
quently the translocation of SREBP2 from cytoplasm to
the nucleus where this transcriptional protein simultan-
eously up-regulates the expression of LDLR and PCSK9;
the latter, by increasing LDL receptors degradation, may
reduce the LDL-C lowering effect of STs. In vitro studies
and some clinical observations support this mechanism.
Dubuc et al. [38] in HepG2 cells and in human pri-
mary hepatocytes found that STs upregulated the ex-
pression of PCSK9 mRNA and that this induction was
dose-dependent and reversed by mevalonate. Clinical
investigations in HCH patients showed a dose-dependent
increase of PCSK9 in plasma during treatment with ator-
vastatin or rosuvastatin [39,40]. The treatment with STs/
EZE combination, through a more pronounced depletion
in hepatic cholesterol content, induced an increase in
plasma PCSK9 more pronounced (~77%) than STs alone
in the same doses (~45%) [39]. These results provide one
possible explanation why increasing doses of STs fail to
achieve a proportional LDL-C reduction (only about 6%
with each doubling of the dose), in view of the dose-
dependent increase of PCSK9 expression induced by STs
and the consequent PCSK9-mediated degradation of
LDLRs [40].
Starting from the finding that ST administration to
Pcsk9 knockout mice produced an exaggerated increase in
LDLRs in liver and enhanced LDL clearance from their
plasma [41], and from the observation that HeFH patients,
who also carried loss of function mutations of PCSK9,
showed a greater than expected reduction of LDL-C levels
during STs therapy [42], novel strategies have been
adopted in experimental animal models to inhibit or re-
duce PCSK9 production or activity; this provides the back-
ground for future therapies aimed to increase the LDL-C
lowering effect of the currently used pharmacological
treatments. These strategies include the PCSK9 gene si-
lencing with modified antisense oligonucletides or short
interfering RNA (siRNAs) directed against the PCSK9
mRNA, monoclonal antibodies directed against circulating
PCSK9 protein which inhibit its binding to LDLR and
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interaction with LDLR [43]. The results till now obtained
have showed that the inhibition of PCSK9 resulted in an
increase of hepatic LDLRs and in a significant reduction
of LDL-C levels, and in a strong additional decrease of
LDL-C in animals receiving STs.
In vitro studies in human hepatoma-derived cell lines
(HepG2 and Huh7 cells) showed that BBR decrease
PCSK9 mRNA and protein levels in a time- and dose-
dependent manner [11,44]. BBR acts inducing a coordin-
ate reduction of the cellular amount of HNF1α and
SREBP2 proteins, and consequently reduces the binding
of these proteins, which synergistically transactivate the
PCSK9 gene transcription to the respective HNF1 and
SRE-1 sequences in the promoter; this mechanism
results in a strong suppression of PCSK9 production
[37]. Moreover, BBR counteracts the stimulating effect
of STs on PCSK9 transcription and increases LDLR
mRNA and LDLR-protein levels [11,37,44]. A previous
study in hyperlipidemic rats showed that the combin-
ation of BBR with simvastatin at low dosage caused a de-
crease in plasma LDL-C and TG significantly higher
than monotherapy with either of these drugs and similar
to that induced by a double dose of simvastatin alone,
and that the combined treatment up-regulated the LDLR
mRNA in rat livers to a level 1.6-fold higher than the
monotherapies did. These results were confirmed in
Chinese patients with moderate HCH treated with sim-
vastatin 20 mg/day plus BBR 1 g/day or with either of
these drugs alone; in these patients the combination
lowered LDL-C and TG to extents much higher than
monotherapy [45]. These findings suggest that BBR
might strengthen in vivo the reduction of plasma LDL-C
induced by the treatment with STs.
On these bases we tested the effect of BBR supplemen-
tation in our HeFH patients. Unfortunately, at the time of
data collection we were unable to measure plasma PCSK9
concentrations before and after BBR supplementation and
consequently we can not prove that the further LDL-C re-
duction obtained with BBR was really mediated by an in-
hibition of PCSK9 expression. However, in these HeFH
patients we observed an inverse correlation between
the reduction of LDL-C levels obtained with STs or
STs + EZE and the additional decreases induced by
BBR (Figure 2). Considering that previous studies found
a direct relationship between the reductions of LDL-C
levels induced by STs and the increases of PCSK9 in
plasma [39,46], our finding of the above mentioned in-
verse correlation might provide an indirect proof of the
BBR-mediated inhibition of PCSK9. Indeed, in the pres-
ence of progressively higher levels of PCSK9, we expect
the inhibitory effect of the fixed dose of BBR on PCSK9
production to be progressively reduced, accounting for a
proportional reduction of the additional LDL-C loweringeffect. However, concomitant or different mechanisms,
such as an increased expression of LDLRs, coupled with
their prolonged half-life, may explain our findings.
Conclusions
Among the available alternative lipid-lowering treatments
of subjects with primary HCH intolerant to STs or refus-
ing therapy with these drugs, we have evaluated the effects
of a nutraceutical pill containing BBR and red yeast rice
and of EZE and have showed the greater efficacy of the
former product. Moreover, with their combination we
observed a decrease in plasma LDL-C and TG comparable
to that induced by the administration of moderate doses
of STs. In patients with HeFH on stable treatment with
LDL-C lowering validated drugs, the supplementation
with the nutraceutical pill resulted in a further decrease of
LDL-C superior to that obtained doubling the dose of ST.
Additional file
Additional file 1: Table S1. Clinical and genetic characteristics of HeFH
patients receiving supplementary treatment with BBR/P/RR.
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